Acumen Pharmaceuticals (ABOS) Income from Continuing Operations (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Income from Continuing Operations of 21154000.0 for Q1 2026, up 14.04% sequentially from 24609000.0 in Q4 2025, and up 26.86% YoY from 16675279.04 in Q1 2025.
Acumen Pharmaceuticals (ABOS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Income from Continuing Operations for 7 years, with the latest figure at 21154000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 26.86% year-over-year to 21154000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 112486000.0 (up 5.24% YoY) and the FY2025 annual result came in at 201858000.0, down 29.31% from the prior year.
- Income from Continuing Operations improved to 21154000.0 in Q1 2026 per ABOS's latest filing, from 24609000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9244000.0 in Q1 2022 and troughed at 51189000.0 in Q3 2022.
- A 5-year average of 23286176.47 and a median of 21569000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 1205.51% in 2022, then jumped 74.77% in 2023.
- Over 5 years, Income from Continuing Operations stood at 14134000.0 in 2022, then fell by 4.03% to 14704000.0 in 2023, then plunged by 161.32% to 38425000.0 in 2024, then soared by 35.96% to 24609000.0 in 2025, then gained by 14.04% to 21154000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21154000.0, 24609000.0, and 25942000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -32.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.54 Mn |
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -24.61 Mn |
| Sep 30, 2025 | -25.94 Mn |
| Jun 30, 2025 | -40.78 Mn |
| Mar 31, 2025 | -28.92 Mn |
| Dec 31, 2024 | -38.43 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -21.57 Mn |
| Mar 31, 2024 | -14.77 Mn |
| Dec 31, 2023 | -14.70 Mn |
| Sep 30, 2023 | -12.92 Mn |
| Jun 30, 2023 | -11.63 Mn |
| Mar 31, 2023 | -13.18 Mn |
| Dec 31, 2022 | -14.13 Mn |
| Sep 30, 2022 | -51.19 Mn |
| Jun 30, 2022 | -22.91 Mn |
| Mar 31, 2022 | -9.24 Mn |
| Dec 31, 2021 | -8.39 Mn |
| Sep 30, 2021 | -3.92 Mn |